Serge Belanger is ranked #651 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Serge Belanger (Needham) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Serge Belanger's stock ratings?

About 64% of Serge's ratings were profitable over a one-year hold, with an average return of +7.1% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Serge Belanger

NDM

Serge Belanger

Needham

Wall Street Analyst

★★★★☆

#651

on 13Foresight · ranked by our own returns

64%

Success Rate

+7.1%

Average Return

23 of 36 calls profitable · +5.1% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

🔒 3-year track record is Pro. Showing 1-year — upgrade.

📈 Across the calls we could measure, roughly 64% of Serge Belanger's ratings turned a profit when each position was held for 1 year — averaging +7.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

155 Buy 34 Hold 0 Sell

Serge's Stock Coverage 27 ratings · 2026-07-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
EOLS Evolus	Jul 08, 2026	HOLD	Strong Buy +116.9% avg upside 9 analysts	—	+0.9%
AMPH Amphastar Pharmaceuticals	Jul 08, 2026	HOLD	Hold +38.8% avg upside 11 analysts	—	-0.9%
BCRX BioCryst	Jun 30, 2026	BUY	Strong Buy +77.0% avg upside 24 analysts	$16.00 53.14% Upside	+1.7%
ARQT Arcutis Biotherapeutics	Jun 30, 2026	BUY	Strong Buy +41.3% avg upside 14 analysts	$36.00 29.72% Upside	+11.9%
PCRX Pacira Pharmaceuticals	Jun 30, 2026	BUY	Buy +52.8% avg upside 21 analysts	$32.00 25.62% Upside	+0.4%
CYTK Cytokinetics	Jun 29, 2026	BUY	Strong Buy +3.4% avg upside 36 analysts	$102.00 20.09% Upside	-2.7%
VRDN Viridian Therapeutics	Jun 29, 2026	BUY	Strong Buy +78.3% avg upside 32 analysts	$34.00 72.27% Upside	+5.1%
OMER Omeros	Jun 26, 2026	HOLD	Buy +102.6% avg upside 14 analysts	—	·
MLTX MoonLake Immunotherapeutics	Jun 22, 2026	BUY	Buy +43.0% avg upside 20 analysts	$30.00 47.41% Upside	-8.1%
OCUL Ocular Therapeutix	Jun 18, 2026	BUY	Strong Buy +141.8% avg upside 21 analysts	$18.00 76.47% Upside	+8.9%
HRTX Heron Therapeutics	Jun 02, 2026	HOLD	Strong Buy +6453.1% avg upside 21 analysts	—	-8.9%
MANE Veradermics, Incorporated	Jun 02, 2026	BUY	Strong Buy +10.8% avg upside 6 analysts	$136.00 13.65% Upside	·
OCS Oculis Holding	Jun 01, 2026	BUY	Strong Buy +181.4% avg upside 11 analysts	$38.00 178.71% Upside	-6.1%
TRVI Trevi Therapeutics	May 20, 2026	BUY	Strong Buy +13.2% avg upside 16 analysts	$23.00 28.83% Upside	+35.8%
CRMD Cormedix	May 14, 2026	BUY	Strong Buy +78.0% avg upside 13 analysts	$15.00 78.57% Upside	+11.3%
VRCA Verrica Pharmaceuticals	May 13, 2026	HOLD	Strong Buy +192.1% avg upside 8 analysts	—	-11.4%
COLL Collegium Pharmaceutical	May 12, 2026	BUY	Strong Buy +19.6% avg upside 8 analysts	$56.00 59.04% Upside	-0.9%
ESPR Esperion	May 12, 2026	HOLD	Buy +693.7% avg upside 22 analysts	—	+1.9%
LQDA Liquidia Technologies	May 11, 2026	BUY	Strong Buy -27.4% avg upside 15 analysts	$70.00 10.11% Downside	+46.7%
XENE Xenon	May 08, 2026	BUY	Strong Buy -8.6% avg upside 28 analysts	$78.00 13.23% Upside	+12.3%
NAMS NewAmsterdam Pharma Company	May 07, 2026	BUY	Strong Buy +33.1% avg upside 18 analysts	$48.00 36.14% Upside	+1.2%
CLSDQ Clearside Biomedical	Dec 23, 2025	HOLD	Hold +11086.5% avg upside 10 analysts	—	-63.9%
AKBA Akebia Therapeutics	Oct 28, 2022	HOLD	Strong Buy +604.7% avg upside 16 analysts	—	+223.1%
CALC CalciMedica	Oct 28, 2022	HOLD	Buy +2964.5% avg upside 9 analysts	—	-61.8%
GREE Greenidge Generation Holdings	Nov 05, 2021	BUY	Buy +398.7% avg upside 5 analysts	$22.00 1011.07% Upside	·
EVFM Evofem Biosciences	Jun 26, 2017	HOLD	Buy +269017.7% avg upside 8 analysts	—	·
CYTOF Altamira Therapeutics	Aug 19, 2016	BUY	Strong Buy +41816.2% avg upside 4 analysts	$5.00 9880.08% Upside	·

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Serge Belanger — Frequently Asked Questions

How accurate are Serge Belanger's stock ratings?

Based on the calls 13Foresight could measure, about 64% of Serge's ratings were profitable over a one-year hold, with an average return of +7.1% per rating, or +5.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Serge ranked on 13Foresight?

Serge Belanger is currently ranked #651 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Serge cover?

Serge most recently has ratings on EOLS, AMPH, BCRX, ARQT, PCRX, CYTK, VRDN, OMER, MLTX, OCUL, HRTX, MANE and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!